Why GlaxoSmithKline plc And Shire plc Are Dividend And Growth Buys

This Fool thinks it’s time to invest in GlaxoSmithKline plc (LON: GSK) and Shire plc (LON: SHP).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) and Shire (LSE: SHP) would be my pick of the pharmaceutical companies to invest in at the moment. While GSK is a dividend investment, Shire is a growth play. Let’s look at each company in turn.

GlaxoSmithKline

Glaxo is one of the world’s largest pharmaceutical companies, with strengths in asthma, cancer, diabetes and digestive diseases. It has been a firm renowned as having one of the strongest drugs pipelines in the pharma industry.

Yet in the last few years it has not quite lived up to expectations. Last year the company was damaged in one of its fastest growing markets by the bribery scandal in China. Sales of several blockbuster drugs have fallen as their patents have expired, while newly launched drugs, although selling well, have not matched the big sellers of yesteryear.

Yet this remains one of the most innovative healthcare businesses in the world. I think what GlaxoSmithKline and the rest of the pharmaceutical industry is learning, just like the TV industry learnt before it, and supermarket retail is learning now, is how to adapt to the world of the long tail.

You see, in the past many drugs were so popular they sold more than the rest of the market put together. You can think of Zantac and Losec as the Jewel in the Crown and Upstairs Downstairs of pharma. These drugs sold in their millions, and made drugs companies billions.

But today if you want to buy a drug because you are suffering from a bit of heartburn, alongside Zantac and Losec you have Nexium, Dexilant, Reglan and perhaps a dozen other branded drugs. The days when one drug grabbed the bulk of the market are gone.

That’s why I think that traditional pharmaceutical companies such as GSK are unlikely to grow quickly. But they are still highly profitable, and generate prodigious amounts of cash. That’s why they are the ideal dividend shares. Glaxo is currently on a 2015 P/E ratio of 16.4 with a dividend yield of 5.2%. That’s a high yield, which is well covered by profits. I view this as a strong dividend buy.

Shire

One of the tragedies of the past was that if you suffered from a rare disease, the likelihood was that there would be no treatment. These days, things are different. Shire is a business built upon the idea that you produce targeted treatments to a wide variety of diseases by use of the latest science and biotechnology.

Shire, instead of being a pharmaceutical titan, is really a network of smaller companies, each designed to tackle a particular ailment. You see, myriad rare diseases now have myriad treatments. And the world of the long tail is about a lot more than spaghetti sauce or TV programmes.

Who would have thought that such an apparently disparate business would be so successful and so profitable? The earnings per share progression shows how quickly this company is growing:

2011: 97p

2012: 86p

2013: 148p

2014: 229p

2015: 245p

A 2014 P/E ratio of 22.0, falling to 20.6 in 2015 sounds expensive, but I think this is a clear growth buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

With an 8% dividend yield, I think this undervalued FTSE stock is a no-brainer buy

With an impressive yield and good track record of payments, Mark David Hartley is considering adding this promising FTSE share…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£9,500 in savings? Here’s how I’d try to turn that into £1,809 a month of passive income

Investing a relatively small amount into high-yielding stocks and reinvesting the dividends paid can generate significant passive income over time.

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

Dividend star Legal & General’s share price is still marked down, so should I buy more?

Legal & General’s share price looks very undervalued against its peers. But it pays an 8%+ dividend yield, and has…

Read more »

Investing Articles

Dividend shares: 1 FTSE 100 stock to consider buying for chunky shareholder income

This company’s ‘clean’ dividend record looks attractive to me and I’d consider buying some of the shares to hold long…

Read more »

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »